Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Cyclophosphamide: Potential Hepatorenal Toxicity and the Possible Therapeutic Role of Mesenchymal Stem Cell-Derived Exosomes in Wistar Rats.

Abdallah AN., Effat H., Mousbah AM., Ahmed HH., Abohashem RS.

Animal Study on Chronic Inflammation, published in J Biochem Mol Toxicol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Biochem Mol Toxicol (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41586570
DOI
10.1002/jbt.70705

Abstract (original English)

This study aimed to examine therapeutic impact of exosomes derived from adipose tissue- mesenchymal stem cells (AD-MSCs-Exos) on a rat model of hepatorenal toxicity. 32 Wistar male rats were grouped into 4 groups: Control group, rats received intraperitoneally (i.p.) phosphate buffered saline (PBS). Cyclophosphamide (CTX) group, rats injected i.p. with a single dose of CTX (50 mg/kg) followed by rotating doses of 8 mg/kg of CTX daily for 2 weeks. CTX + AD-MSCs group, rats infused with (1 × 10 6 AD-MSCs cells/rat) dissolved in PBS intravenously (i.v.) day after day for 1 week starting from second day of CTX last dose. CTX + AD-MSCs-Exos group, rats injected with 100 μg of Exos derived from AD-MSCs in 1 ml PBS by i.v. injection for 1 week starting from second day of CTX last dose. 5 weeks following initial CTX dose, blood, liver, and kidneys extracted. Serum alanine transaminase (ALT), aspartate transaminase (AST), creatinine and urea levels; hepatic malate dehydrogenase (MDH) and glutamate dehydrogenase (GLDH); renal kidney injury molecule-1 (KIM-1) and clusterin measured. Tumor necrosis factor alpha (TNF-α) and malonialdehyde (MDA) were estimated in hepatic and renal tissues. Furthermore, nuclear factor kappa B/toll like receptor-4 (NF-κB/TLR-4), nuclear factor erythroid 2- related factor 2/heme oxygenase-1 (Nrf-2/HO-1) and BCL-2-associated X protein/B-cell lymphoma 2 (Bax/Bcl-

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCyclophosphamideExosomesRats, WistarMaleMesenchymal Stem CellsRatsKidneyLiverChemical and Drug Induced Liver Injury

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research